Martin Bexon

3.4k total citations
25 papers, 161 citations indexed

About

Martin Bexon is a scholar working on Immunology, Genetics and Epidemiology. According to data from OpenAlex, Martin Bexon has authored 25 papers receiving a total of 161 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 7 papers in Genetics and 5 papers in Epidemiology. Recurrent topics in Martin Bexon's work include Immunodeficiency and Autoimmune Disorders (9 papers), Glioma Diagnosis and Treatment (4 papers) and Cancer Research and Treatments (4 papers). Martin Bexon is often cited by papers focused on Immunodeficiency and Autoimmune Disorders (9 papers), Glioma Diagnosis and Treatment (4 papers) and Cancer Research and Treatments (4 papers). Martin Bexon collaborates with scholars based in United States, Switzerland and Australia. Martin Bexon's co-authors include Mikhail Rojavin, John‐Philip Lawo, Jonathan M. Edelman, Stephen Jolles, Carl M. J. Kirkpatrick, Jeffrey S. Baggish, Marc Pfister, Jagdev Sidhu, Michael Borte and Jianfeng Lü and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Allergy and Clinical Immunology and European Respiratory Journal.

In The Last Decade

Martin Bexon

24 papers receiving 159 citations

Peers

Countries citing papers authored by Martin Bexon

Since Specialization

Citations

This map shows the geographic impact of Martin Bexon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Bexon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Bexon more than expected).

Fields of papers citing papers by Martin Bexon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Bexon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Bexon. The network helps show where Martin Bexon may publish in the future.

Co-authorship network of co-authors of Martin Bexon

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Bexon. A scholar is included among the top collaborators of Martin Bexon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Bexon. Martin Bexon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial 2024 ·EClinicalMedicine ·Nicola Brice, Mark Carlton, David Margolin, Martin Bexon, Kim L. Matthews, Lee A. Dawson, Aaron Ellenbogen, C. Warren Olanow, Jordan Dubow, Karl Kieburtz	5
2	743 Pharmacokinetic and pharmacodynamic profile of a first-in-human study with MDNA11, an engineered long-acting beta-only IL-2 agonist 2022 ·Regular and Young Investigator Award Abstracts ·Minh D. To, (unknown), (unknown), Carole L. Galligan, Kritika Mehta, Victoria Atkinson, Martin Bexon, Jermaine Coward, Jenny Lee, Charlotte Lemech, Peter Lloyd, Jesús Fuentes‐Antrás, Arash Yavari, (unknown)	0
3	Building an External Control Arm for Development of a New Molecular Entity: An Application in a Recurrent Glioblastoma Trial for MDNA55 2022 ·Statistics in Biosciences ·(unknown), (unknown), Martin Bexon, Chandtip Chandhasin, (unknown), (unknown), (unknown)	4
4	CLRM-09. INCORPORATING EXTERNAL CONTROL ARM IN MDNA55 RECURRENT GLIOBLASTOMA REGISTRATION TRIAL 2021 ·Neuro-Oncology Advances ·(unknown), (unknown), Martin Bexon, Nicholas Butowski, Chandtip Chandhasin, (unknown), Sunit Das, (unknown), (unknown), David A. Reardon, Martin Roessner, John H. Sampson	3
5	MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control. 2020 ·Journal of Clinical Oncology ·John H. Sampson, Achal S. Achrol, Manish K. Aghi, (unknown), Martin Bexon, Steven Brem, Andrew Brenner, Chandtip Chandhasin, Sajeel Chowdhary, (unknown), Sunit Das, Seunggu J. Han, Santosh Kesari, (unknown), (unknown), Dina Randazzo, Michael A. Vogelbaum, Frank D. Vrionis, Mirosław Ząbek, Nicholas Butowski	10
6	MDNA55: A locally administered IL4 guided toxin as a targeted treatment for recurrent glioblastoma. 2019 ·Journal of Clinical Oncology ·Dina Randazzo, Achal S. Achrol, Manish K. Aghi, Martin Bexon, Steven Brem, Andrew Brenner, Nicholas Butowski, Chandtip Chandhasin, Sajeel Chowdhary, (unknown), John Floyd, Santosh Kesari, (unknown), (unknown), Michael A. Vogelbaum, Frank D. Vrionis, Mirosław Ząbek, John H. Sampson	3
7	ATIM-30. COMBATING RECURRENT GLIOBLASTOMA WITH MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, THROUGH MRI-GUIDED CONVECTIVE DELIVERY 2019 ·Neuro-Oncology ·John H. Sampson, Achal S. Achrol, Manish K. Aghi, (unknown), Steven Brem, Andrew Brenner, Nicholas Butowski, Chandtip Chandhasin, Sajeel Chowdhary, (unknown), John Floyd, Santosh Kesari, (unknown), (unknown), Dina Randazzo, Michael A. Vogelbaum, Frank D. Vrionis, Mirosław Ząbek, Martin Bexon	1
8	ATIM-05. INTRATUMORAL DELIVERY OF MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, BY MRI-GUIDED CONVECTIVE DELIVERY FOR THE TREATMENT OF RECURRENT GLIOBLASTOMA 2018 ·Neuro-Oncology ·Achal S. Achrol, Martin Bexon, (unknown), Andrew Brenner, Nicholas Butowski, Santosh Kesari, (unknown), (unknown), Dina Randazzo, Michael A. Vogelbaum, Mirosław Ząbek, John H. Sampson	1
9	ATIM-16. MRI-GUIDED CONVECTIVE DELIVERY OF MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY FOR THE TREATMENT OF RECURRENT GLIOBLASTOMA 2017 ·Neuro-Oncology ·(unknown), Achal S. Achrol, Manish K. Aghi, Martin Bexon, Andrew Brenner, Nicholas Butowski, (unknown), John Floyd, Russell R. Lonser, (unknown), (unknown), Toral Patel, Dina Randazzo, Mark M. Souweidane, Michael A. Vogelbaum, Frank D. Vrionis, John H. Sampson	1
10	Population pharmacokinetics of A₁-PI in patients with Alpha-1 antitrypsin deficiency 2015 ·Michael A. Tortorici, (unknown), Martin Bexon, Robert A. Sandhaus, Jonathan Burdon, Eeva Piitulainen, Niels Seersholm, James Stocks, Noel G. McElvaney, Kenneth R. Chapman, Jonathan M. Edelman	2
11	Safety of bi-weekly infusion of A₁-PI augmentation therapy in RAPID 2015 ·Niels Seersholm, Robert A. Sandhaus, Kenneth R. Chapman, Jonathan Burdon, Eeva Piitulainen, James Stocks, Michael A. Tortorici, (unknown), (unknown), Martin Bexon, Jonathan M. Edelman, Noel G. McElvaney	4
12	Integrated safety across six clinical trials of alpha-1 augmentation therapy 2014 ·European Respiratory Journal ·Robert A. Sandhaus, Kenneth R. Chapman, Jonathan Burdon, Eeva Piitulainen, Niels Seersholm, James Stocks, Jonathan M. Edelman, Martin Bexon, Liping Huang, Noel G. McElvaney	2
13	Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases 2014 ·Journal of Clinical Immunology ·Hirokazu Kanegane, Kohsuke Imai, Masafumi Yamada, Hidetoshi Takada, Tadashi Ariga, Martin Bexon, Mikhail Rojavin, Wilson Hu, Midori Kobayashi, John‐Philip Lawo, Shigeaki Nonoyama, Toshiro Hara, Toshio Miyawaki	28
14	Safety, Tolerability, and Efficacy Of Hizentra® In Japanese Patients With Primary Immunodeficiency Over 48 Weeks 2014 ·Journal of Allergy and Clinical Immunology ·Kohsuke Imai, Hirokazu Kanegane, Masafumi Yamada, Hidetoshi Takada, Tadashi Ariga, Midori Kobayashi, Mikhail Rojavin, Martin Bexon, Shigeaki Nonoyama, Toshiro Hara, Toshio Miyawaki	1
15	Long-Term Efficacy and Tolerability of 20% Scig in the Treatment of Patients with Primary Immunodeficiency Disease 2013 ·Journal of Allergy and Clinical Immunology ·Michael Borte, Richard L. Wasserman, Mikhail Rojavin, Martin Bexon, Stephen Jolles	1
16	Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease 2013 ·Clinical Immunology ·Stephen Jolles, Michael Borte, Robert P. Nelson, Mikhail Rojavin, Martin Bexon, John‐Philip Lawo, Richard L. Wasserman	27
17	Pharmacokinetic Modeling and Simulation of Biweekly Subcutaneous Immunoglobulin Dosing in Primary Immunodeficiency 2013 ·Postgraduate Medicine ·Cornelia B. Landersdorfer, Martin Bexon, Jonathan M. Edelman, Mikhail Rojavin, Carl M. J. Kirkpatrick, Jianfeng Lü, Marc Pfister, Jagdev Sidhu	30
18	Switching From Monthly Intravenous to Biweekly Subcutaneous Immunoglobulin: A Pharmacokinetic Modeling and Simulation Approach 2013 ·Journal of Allergy and Clinical Immunology ·Mikhail Rojavin, Cornelia B. Landersdorfer, Martin Bexon, Marc Pfister, Jagdev Sidhu	1
19	Increased Frequency of Infections at the End of the IVIG Dosing Cycle: Effect Characterization from Three Phase III Studies 2012 ·Journal of Allergy and Clinical Immunology ·Martin Bexon, Jeffrey S. Baggish, Mikhail Rojavin, M. S. Berger, O. Zenker	4
20	Higher Doses of Subcutaneous IgG Reduce Resource Utilization in Patients with Primary Immunodeficiency 2011 ·Journal of Clinical Immunology ·Élie Haddad, Melvin Berger, (unknown), Christopher A. Jones, Martin Bexon, Jeffrey S. Baggish	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact